2'-Methyl-4'-(5-methyl-1,3,4-oxadiazol-2-yl)biphenyl-4-carboxylic acid → 2,3-Dihydro-1'-methyl-5-(2'-methyl-4'-(5-methyl-1,3,4-oxadiazol-2-yl)biphenyl-4-carbonyl)spiro[furo[2,3-f]indole-3,4'-piperidine]

Participants

Role	Name	HCID	Charge
Reactant	2'-Methyl-4'-(5-methyl-1,3,4-oxadiazol-2-yl)biphenyl-4-carboxylic acid	HCID 18690066	—
Reactant	1-(6-Bromo-5-hydroxy-2,3-dihydro-1H-indol-1-yl)ethan-1-one	HCID 21948380	—
Reactant	2,3-Dihydro-1'-methylspiro[furo[2,3-f]indole-3,4'-piperidine]	HCID 70198004	—
Product	2,3-Dihydro-1'-methyl-5-(2'-methyl-4'-(5-methyl-1,3,4-oxadiazol-2-yl)biphenyl-4-carbonyl)spiro[furo[2,3-f]indole-3,4'-piperidine]	HCID 21833853	—

Reaction Steps

The title compound was prepared from 2,3-dihydro-1'-methylspiro[furo[2,3-f]indole-3,4'-piperidine] (D7) and 2'-methyl-4'-(5-methyl-1,3,4-oxadiazol-2-yl)biphenyl-4-carboxylic acid (D11) using a similar procedure to Example 8 (22%). This was converted to its oxalate salt, which crystallised from acetone/methanol as a white solid mp 234-237° C.

Provenance & Evidence

DOI	10.6084/m9.figshare.5104873.v1
Patent number	US05972951
Source dataset	uspto-grants-1999_10
ORD ID	ord-bc131c666a3848bda30bb7eada4c8076
Source note	uspto-grants-1999_10